Jiangsu Hengrui Medicine
600276.SS
#522
Rank
NZ$84.50 B
Marketcap
NZ$12.73
Share price
-0.04%
Change (1 day)
-17.09%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Earnings for Jiangsu Hengrui Medicine (600276.SS)

Earnings in 2026 (TTM): NZ$2.56 Billion

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current earnings are NZ$4.79 Billion. In 2024 the company made an earning of NZ$1.80 Billion, an increase over its 2023 earnings that were of NZ$1.19 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Jiangsu Hengrui Medicine from 2002 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) NZ$2.56 B
2024 NZ$1.80 B50.59%
2023 NZ$1.19 B11.35%
2022 NZ$1.07 B-13.91%
2021 NZ$1.24 B-34.08%
2020 NZ$1.89 B16.28%
2019 NZ$1.62 B32.92%
2018 NZ$1.22 B20.82%
2017 NZ$1.01 B23.8%
2016 NZ$0.81 B11.25%
2015 NZ$0.73 B39.52%
2014 NZ$0.52 B20.71%
2013 NZ$0.43 B11.46%
2012 NZ$0.39 B29.6%
2011 NZ$0.30 B31.28%
2010 NZ$0.23 B27.89%
2009 NZ$0.18 B5.84%
2008 NZ$0.17 B79.89%
2007 NZ$94.68 M32.93%
2006 NZ$71.23 M38.14%
2005 NZ$51.56 M21.56%
2004 NZ$42.42 M13.95%
2003 NZ$37.22 M38.06%
2002 NZ$26.96 M